Archie Tse

4.4k citations

59 papers · 3.3k indexed · 1 hit paper · h-index 23

Oncology top 1%
- Cancer-related Molecular Pathways 13
- Cancer Immunotherapy and Biomarkers 11
- Colorectal Cancer Treatments and Studies 9
Pulmonary and Respiratory Medicine top 2%
- Lung Cancer Treatments and Mutations 7
Hepatology top 5%
Cell Biology top 5%
- Microtubule and mitosis dynamics 7
Molecular Biology top 5%
- Cancer therapeutics and mechanisms 13
- DNA Repair Mechanisms 7
Cancer Research
- Cancer Genomics and Diagnostics 7

Co-authors: Gary K. Schwartz Richard D. Carvajal David P. Kelsen Manish A. Shah Nancy E. Kemeny Jinru Shia David S. Klimstra Leonard B. Saltz
Cited by: Oncology Pulmonary and Respiratory Medicine Hepatology
Partner nations: United States United Kingdom China

In The Last Decade

Archie Tse

57 papers receiving 3.2k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2005 Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

Peers

Countries citing papers authored by Archie Tse

Since Specialization

Citations

This map shows the geographic impact of Archie Tse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Archie Tse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Archie Tse more than expected).

Fields of papers citing papers by Archie Tse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Archie Tse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Archie Tse. The network helps show where Archie Tse may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Archie Tse, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Archie Tse Line = papers co-authored together Archie Tse links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	LBA48 BURAN: A phase III study of buparlisib (BUP) plus paclitaxel (PAC) in patients with PD-1(PD-L1)-pretreated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) Denis Soulières,Yi‐Chun Liu,Kedar Kirtane,Stefan Kasper‐Virchow,Tomasz Rutkowski,Federico de la Rosa,N. Kiyota,Francis P. Worden,M-H. Yang,Anil K. Giri,Amaury Daste,Erika Hitre,Akihito Tsuji,N.F. Saba,Ye Guo,J.D. Assaf Pastrana,Kevin Dreyer,S. Lu,Archie Tse,Lisa Licitra	2025	0
2	Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study Sarwan Bishnoi,Dusan Kotasek,Morteza Aghmesheh,Thomas Yau,Rasha Cosman,Amy Prawira,Maggie Moore,Stephen L. Chan,Andrew Mant,Richard Eek,Robert Zielinski,Rila Su,Z. Pan,Yiding Ma,Fei Li,Peiqi Li,Archie Tse	2024	1
3	Tumor growth inhibition‐overall survival modeling in non‐small cell lung cancer: A case study from GEMSTONE‐302 Yucheng Sheng,Shu‐Wen Teng,Jingru Wang,Hao Wang,Archie Tse	2023	9
4	Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia Zenglian Yue,Z. Pan,Siyuan Wang,Archie Tse,Yucheng Sheng	2023	1
5	A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer Daphne Day,John Park,Jermaine Coward,Ben Markman,Charlotte Lemech,James Kuo,Amy Prawira,Michael P. Brown,Sarwan Bishnoi,Dusan Kotasek,Robert Matthew Strother,Rasha Cosman,Rila Su,Yiding Ma,Zenglian Yue,Hui-Han Hu,Rachel Wu,Peiqi Li,Archie Tse	2023	4
6	138P Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors Sarwan Bishnoi,Thomas Yau,Rasha Cosman,M. Aghmesheh,Miranda A. Moore,Stephen L. Chan,Andrew Mant,Richard Eek,R. Zielinski,P. Li,H. Wang,Y. Ma,Archie Tse	2021	2
7	987P A phase Ib study of the PD-1 antagonist CS1003 plus lenvatinib (LEN) in Chinese patients (pts) with the first-line (1L) unresectable hepatocellular carcinoma (uHCC) Lin Shen,Y. Zhang,Ye Guo,W. Li,J. Gong,Zhigang Ma,Wei Peng,Na Wang,Jingxian Ni,Qi Qi,Yan Ma,Zike Qin,Archie Tse	2020	9
8	Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition Jo Ishizawa,Kenji Nakamaru,Takahiko Seki,Koichi Tazaki,Kensuke Kojima,Dhruv Chachad,Ran Zhao,Lauren Heese,Wencai Ma,Man Chun John,Courtney D. DiNardo,Sherry Pierce,Keyur P. Patel,Archie Tse,R. Eric Davis,Arvind Rao,Michael Andreeff	2018	44
9	Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas Kevin J. Harrington,Joshua Brody,M. Ingham,James Strauss,Sašo Čemerski,M. Wang,Archie Tse,Anuradha Khilnani,Aurélien Marabelle,Talia Golan	2018	201
10	A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development Cong Chen,Keaven M. Anderson,Devan V. Mehrotra,Eric H. Rubin,Archie Tse	2017	41
11	Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase Samuel McNeely,Chiara Conti,Tahir Sheikh,Himali Patel,Sonya Zabludoff,Yves Pommier,Gary K. Schwartz,Archie Tse	2010	68
12	Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival William R. Jarnagin,Lawrence H. Schwartz,David H. Gültekin,Mithat Gönen,Dana Haviland,Jinru Shia,M.I. D’Angelica,Yuman Fong,Ronald P. DeMatteo,Archie Tse,Leslie H. Blumgart,Nancy E. Kemeny	2009	138
13	A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies Archie Tse,Nian Wu,Dina Patel,Dana Haviland,Nancy E. Kemeny	2009	10
14	A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors Archie Tse,David S. Klimstra,Mithat Gönen,Manish Shah,Tahir Sheikh,Rachel Sikorski,Richard D. Carvajal,Janet Mui,Caroll Tipian,Eileen M. O’Reilly,Ki Wook Chung,Robert G. Maki,Robert A. Lefkowitz,Karen T. Brown,Katia Manova‐Todorova,Nian Wu,Merrill J. Egorin,David P. Kelsen,Gary K. Schwartz	2008	49
15	AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies Sonya Zabludoff,Chun Deng,Michael Grondine,Adam Sheehy,Susan Ashwell,Benjamin Caleb,Stephen Green,Heather Haye,Candice L. Horn,James W. Janetka,Dongfang Liu,Elizabeth Mouchet,Shannon Ready,Judith L. Rosenthal,Christophe Quéva,Gary K. Schwartz,Karen J. Taylor,Archie Tse,Graeme E. Walker,Anne M. White	2008	333
16	CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo Archie Tse,Katherine G. Rendahl,Tahir Sheikh,Haider Cheema,Kim Aardalen,Millicent Embry,Sylvia Ma,Edward J. Moler,Zhi Ni,Daniel E. Lopes de Menezes,Barbara Hibner,Thomas G. Gesner,Gary K. Schwartz	2007	117
17	A phase I clinical and pharmacokinetic study of escalating doses of fixed rate and escalating infusion duration of gemcitabine given via an intrahepatic pump for patients with hepatic metastases Archie Tse,Greer A. Raggio,M. Morse,Nancy E. Kemeny	2006	1
18	Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe Archie Tse,Gary K. Schwartz	2004	76
19	Mutations in the Reduced Folate Carrier Gene Which Confer Dominant Resistance to 5,10-Dideazatetrahydrofolate Archie Tse,Kevin E. Brigle,Shirley M. Taylor,Richard G. Moran	1998	52
20	Cellular Folates Prevent Polyglutamation of 5,10-Dideazatetrahydrofolate Archie Tse,Richard G. Moran	1998	29

About Archie Tse

Archie Tse is a scholar working on Oncology, Hepatology and Cancer Research, having authored 59 papers that have together received 3.3k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (13 papers), Cancer-related Molecular Pathways (13 papers), Cancer Immunotherapy and Biomarkers (11 papers), Colorectal Cancer Treatments and Studies (9 papers), DNA Repair Mechanisms (7 papers), Microtubule and mitosis dynamics (7 papers), Cancer Genomics and Diagnostics (7 papers) and Lung Cancer Treatments and Mutations (7 papers). The work is most often cited by research in Oncology (2.0k citations), Pulmonary and Respiratory Medicine (947 citations) and Hepatology (210 citations). Archie Tse has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Gary K. Schwartz, Richard D. Carvajal, David P. Kelsen, Manish A. Shah, Nancy E. Kemeny, Jinru Shia, David S. Klimstra, Leonard B. Saltz, Deborah Schrag and Audrey Hamilton.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact